Nona Biosciences

The Nona Biosciences team will be in San Francisco for the #JPMHealthcareConference. As a courtesy to our partners and prospective collaborators, we will have a private meeting room available at the Galleria Park Hotel (191 Sutter St) throughout the day for focused discussions. If you’re attending and would like to connect or reserve time, please reach out to us here: https://lnkd.in/eyHStt4y or connect directly with Jiyong Zhang and Sean Cullen We look forward to meaningful conversations around innovation, collaboration, and advancing next-generation biotherapeutics. #JPM2026 #NonaBiosciences #Partnering #Biopharma #BiotechGlobalForum

We are pleased to share that Nona Biosciences has entered into a collaboration agreement with Link Cell Therapies to advance next-generation CAR-T cell therapies. 🎉 🎉 Under this multi-target antibody discovery collaboration, we will leverage our fully human HCAb Harbour Mice® platform together with the innovative direct CAR-function-based HCAb library screening platform, NonaCarFx™, to generate novel HCAb candidates for CAR-T applications. Fully human heavy chain-only antibodies offer important advantages for cell therapy development, including reduced immunogenicity and greater flexibility in CAR design. Through this collaboration, we aim to combine Nona’s antibody discovery capabilities with Link Cell Therapies’ expertise in logic-gated CAR-T technologies to support the development of differentiated CAR-T candidates. We look forward to working with Link Cell Therapies as we advance innovative therapies in the evolving CAR-T landscape. 🤝 🤝 👉 Learn more about this collaboration: https://lnkd.in/gXMXBcPc #Collaboration #CellTherapy #AntibodyDiscovery #Cancer

When it comes to next-generation biotherapeutic design, fully human VH-based architectures support the modular, compact constructs used in advanced modalities. For a condensed system view, this infographic shows how Harbour Mice® and Nona Biosciences’ HCAb platforms enable modular VH binder discovery and design across immune cell engagers, CAR-based therapies, ADCs, and targeted delivery platforms. View the infographic: https://lnkd.in/eHm3paTn #AntibodyDesign #Biotherapeutics #HCAb #AntibodyEngineering #NonaBiosciences

With therapeutic constructs becoming more modular and complex, compact binders are emerging as versatile building blocks for next-generation biotherapeutic design. Our latest blog looks at how fully human single variable heavy (VH) domains are enabling advanced therapeutic architectures, including: 👉 Why compact VH domains enable greater construct flexibility 👉 How VH binders support modular architectures across immune cell engagers, CAR-based therapies, and other advanced modalities 👉 What makes fully human VH domains suitable as plug-and-play design elements Read here: https://lnkd.in/e4mGq2Ya #AntibodyEngineering #Biotherapeutics #DrugDiscovery #HCAb #NonaBiosciences

Thank you to everyone who joined us for the Nona Biosciences Holiday Happy Hour in San Diego last week. It was a wonderful evening filled with meaningful conversations, new connections, and shared excitement across the biotech and biopharma community. As we close out the year, we’re grateful for the opportunity to connect with so many scientists, innovators, and partners shaping the future of life sciences. We are always happy to continue the conversation and to support your next-generation therapeutic programs. Contact us to learn more: https://lnkd.in/ebi9FkEX #AntibodyDiscovery #HCAb #Bispecific #ADC #SanDiegoBiotech

Thank you to everyone who joined us for the Nona Biosciences Holiday Happy Hour in South San Francisco last week. It was a fantastic evening filled with meaningful conversations, new connections, festive drinks, and fun games with the Bay Area’s biotech and biopharma community. As we close out the year, we’re grateful for the opportunity to connect with so many scientists, innovators, and partners shaping the future of life sciences. We are always happy to continue the conversation and to support your next-generation therapeutic programs. Contact us to learn more: https://lnkd.in/ec6w-GrJ #AntibodyDiscovery #HCAb #Bispecific #ADC #BayAreaBiotech

We are glad to share that Nona Biosciences has expanded its integrated discovery and development framework to support early clinical development and Investigator-Initiated Trials (IITs), extending our capabilities beyond discovery and IND-enabling activities. 👏 👏 The expanded framework strengthens CMC development, toxicology, and GMP manufacturing capabilities and builds on Nona’s proprietary platforms, including Harbour Mice®, HBICE®, Hu-mAtrIx™, NonaCarFx™ and Modalities-on-Demand™. Through strategic partnerships, platform acquisitions, and internal technology innovation, we support efficient clinical trial initiation while maintaining rigorous scientific and quality standards. By leveraging established infrastructure and IIT experience, particularly through our partnerships in China, Nona continues to enhance operational efficiency and global development readiness. This represents a natural progression of our strategic vision, supporting efficient clinical translation through integrated, scalable platforms. We look forward to working with partners worldwide to advance biologics from discovery through early clinical development! 🤝 🤝 👉 Learn more about this exciting news: https://lnkd.in/getFKZYZ #BiologicsInnovation #AntibodyDiscovery #EarlyClinicalDevelopment #CMC #IIT 

We are delighted to announce a strategic collaboration with Porton Pharma Solutions Ltd. (“Porton”), a global leading CDMO company, to jointly advance the development and commercialization of complex antibody therapies, including bispecific antibodies, multi-specific antibodies, and more. 🎉 🎉 🎉 This collaboration combines Nona’s fully human antibody discovery capabilities, driven by the Harbour Mice® antibody technology platform, with Porton’s expertise in CMC development, global regulatory compliance, and GMP manufacturing. Together, we aim to address key challenges across the full lifecycle development of complex antibodies, including process stability, purification analysis, regulatory quality, cost optimization, and supply chain management. 👏 👏 As part of the collaboration, the two companies will establish a joint development and management team to operate the projects for all stages across antibody discovery, CMC, regulatory, GMP operation, clinical supply, and commercialization. The initial focus will be on complex antibody therapies, with the potential to expand into additional new modality areas.🤝 🤝 🤝 Through this collaboration, Nona Biosciences will be able to more efficiently translate its industry-leading antibody discovery technologies into globally competitive clinical candidates and commercial products, providing more reliable and sustainable value to our customers and partners. 🌟 🌟 #StrategicCollaboration #ComplexAntibodies #BispecificAntibodies #MultispecificAntibodies #CDMO #NewModality

Compact binders are changing how next-generation biotherapeutics are designed. Our latest blog explores how fully human single variable heavy (VH) domains are emerging as versatile building blocks for modern biotherapeutic development, including: 👉 Why compact, fully human VH domains enable greater design flexibility than traditional antibody formats 👉 How VH binders support innovative architectures for CARs, immune cell engagers, and other advanced modalities 👉 What makes VH domains effective plug-and-play modules, combining compact size, high affinity, and reduced immunogenicity Read here: https://lnkd.in/eKkBfNAy #AntibodyEngineering #Biotherapeutics #DrugDiscovery #NonaBiosciences #HCAb

To our partners, future partners, community, and employees, Nona Biosciences wishes you a warm and meaningful holiday season. Thank you for your support, collaboration, and commitment throughout the year. Your contributions, whether through scientific discovery, shared expertise, or the pursuit of progress, have enriched our work and the broader biotech community. As we welcome 2026, we look forward to building new partnerships, strengthening existing ones, and continuing our shared mission to advance transformative therapies. #NonaBiosciences #HCAb #BioTech #antibodies #celltherapy #genetherapy